Drug Profile
Zelicapavir - Enanta Pharmaceuticals
Alternative Names: EDP-938; EP 023938Latest Information Update: 29 Nov 2023
Price :
$50
*
At a glance
- Originator Enanta Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Respiratory syncytial virus infections
Most Recent Events
- 30 Sep 2023 Enanta Pharmaceuticals terminates phase-II trial in Respiratory syncytial virus infections (In adolescents, In adults) in United Kingdom, Turkey, Spain, South Africa, Taiwan, Poland, Mexico, South Korea, Italy, Israel, Greece, Germany, France, China, Canada, Belgium, Australia, Argentina, Colombia (PO) before September 2023(NCT04633187) (EudraCT2020-002213-18)
- 09 Oct 2022 Phase-II clinical trials in Respiratory syncytial virus infections (In infants) in United Kingdom, Taiwan, Spain, South Africa, Romania, New Zealand, Poland, Mexico, South Korea, Israel, Germany, Brazil, Australia, Argentina (PO), prior to October 2022 (NCT04816721)
- 30 Sep 2022 Antimicrobial data from preclinical studies in Respiratory syncytial virus infections released by Enanta Pharmaceuticals